Uses of epithelial-to-mesenchymal inhibitors in generating pacemaker cells
AssigneesEmory University, Children's Healthcare of Atlanta, Inc.
InventorHee Cheol Cho
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of generating pacemaker cells for use in therapeutic strategies that address a heart that beats abnormally. In certain embodiments, one mixes cells with an epithelial-to-mesenchymal transformation inhibitor in combination with a nucleic acid encoding a transcription factor such as a vector that encodes a transcription factor such as Tbx18 in operable combination with a eukaryotic promoter to produce pacemaker cells that are then transplanted into the heart.
Claims8
A method of treating a heart from beating abnormally comprising implanting an effective amount of spontaneously beating expanded cells into the heart of a subject in need thereof, wherein the spontaneously beating expanded cells are made by a process comprising mixing cardiomyocytes with
- a) an epithelial-to-mesenchymal transformation inhibitor, wherein the epithelial-to-mesenchymal transformation inhibitor is 3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide or salt thereof, and
- b) a nucleic acid encoding Tbx18;
- thereby delivering a) and b) into the cardiomyocytes,
- wherein the cardiomyocytes proliferate after mixing with a) and b), forming spontaneously beating expanded cells.
A method of treating or preventing a heart from beating abnormally comprising administering an effective amount of an epithelial-to-mesenchymal transformation inhibitor, wherein the epithelial-to-mesenchymal transformation inhibitor is 3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide or salt thereof, in combination with a nucleic acid encoding Tbox18 to a subject in need thereof.
Dependencies are inferred from the claim text.